An ancient energy currency refuels RNA synthesis
A research team in Tokyo has characterized a single enzyme capable of generating all four ribonucleoside triphosphates (NTPs) from inexpensive precursors, potentially rewiring how labs and manufacturers make RNA. The enzyme-a polyphosphate kinase 2 dubbed MAN PPK2-uses inorganic polyphosphate as its phosphate donor to convert nucleoside mono‑ and diphosphates into the activated triphosphates required for in vitro transcription (IVT). The work was released on January 8, 2026 in Nature Communications and announced publicly on January 22, 2026, putting it on the radar of vaccine makers, contract development and manufacturing organizations, and public‑sector biodefense programs.
“We focused on a specific polyphosphate (PolyP) kinase 2 enzyme, MAN, derived from Mangrovibacterium marinum, a marine-sourced bacterium,” explains Matsuura. “Surprisingly, this enzyme could convert all common RNA nucleotides with remarkable efficiency.”
By eliminating multienzyme phosphorylation cascades and expensive energy donors, a MAN PPK2‑driven workflow could lower unit costs for RNA synthesis and simplify supply chains. It also taps a chemically stable, readily available energy source: linear chains of orthophosphate that are trivial to store and handle at scale-essential features if RNA platforms are to be deployed reliably in low‑resource or emergency settings.
Why a single enzyme changes IVT economics
For industrial IVT, NTPs sit at the intersection of science, procurement, and policy: they are technically demanding to make, heavily quality‑controlled, and acutely price‑sensitive. That combination has turned NTPs into a strategic chokepoint for both private and public mRNA programs.
- NTPs are cost and logistics hotspots in RNA production; conventional routes either purchase high‑purity NTPs or assemble them through multi‑step phosphorylation using ATP or phosphocreatine systems.
- Polyphosphate is inexpensive, nonvolatile, and shelf‑stable, enabling on‑demand NTP generation close to the point of use.
- Broad substrate tolerance in MAN PPK2 collapses four separate phosphorylation lines into one biocatalyst, reducing process complexity and the number of raw materials to qualify.
“While this kind of broad activity is unusual in modern enzymes, it may reflect how primitive biological systems made do with just a few enzymes,” comments Longo. For today’s manufacturers, the same breadth could translate into fewer single‑source reagents and more resilient pandemic‑response capacity.
How MAN PPK2 could reshape mRNA manufacturing stacks
Viewed from a plant‑design perspective, MAN PPK2 doesn’t merely swap one reagent for another; it rebalances the whole IVT stack, from planning and procurement to equipment and quality control.
| Process layer | Conventional IVT (purchased NTPs or ATP-fueled cascades) | IVT with MAN PPK2 and polyphosphate |
|---|---|---|
| NTP supply | Bulk NTP procurement; cold‑chain and batch‑specific impurity profiles | On‑site NTP generation from NMP/NDP substrates and PolyP |
| Energy donor | ATP, phosphocreatine, acetyl phosphate, or high‑energy salts | Inorganic polyphosphate (stable, low cost) |
| Enzyme burden | Multiple kinases and regeneration enzymes | Single kinase (MAN PPK2) for all four RNA bases |
| Reaction design | Separate NTP prep plus IVT; or complex co‑regeneration schemes | One‑pot NTP formation feeding directly into T7/RNA polymerase IVT |
| Scalability | Sensitive to NTP pricing and lead times | Scales with commodity PolyP and base precursors |
| Sustainability | High‑energy donors and waste salts | PolyP is nontoxic and widely produced; fewer auxiliary reagents |
Platform architecture: integrating MAN PPK2 into IVT lines
Translating a single‑enzyme concept into a reliable platform will hinge on how biomanufacturers architect their upstream and mid‑stream operations. Early adopters are likely to pilot MAN PPK2 in modular skids that can be slotted into existing IVT suites with minimal disruption.
- Upstream: qualify PolyP chain length distribution; select buffer and divalent ions compatible with MAN PPK2 activity and with downstream RNA polymerase.
- One‑pot mode: stage NMP/NDP substrates with MAN PPK2 to generate NTPs in situ, then trigger IVT by adding polymerase and template DNA; or run a short pre‑charge to reach target NTP levels before transcription.
- Continuous mode: feed PolyP and NMP/NDP at controlled rates; use inline conductivity/UV to monitor NTP build‑up; couple to tangential flow filtration for salt management.
- Decentralized manufacturing: leverage PolyP stability for room‑temperature raw‑material storage; evaluate lyophilized MAN PPK2 cartridges for field‑deployable RNA production.
Data integrity, security, and quality by design
Because MAN PPK2 enables more distributed and potentially smaller‑footprint RNA plants, it also sharpens questions of oversight: regulators and health ministries will want assurance that a decentralized network can maintain comparable data integrity and quality standards to centralized facilities.
- Digital batch records: enforce parameter ranges for PolyP concentration, pH, Mg2+, and residence time; checksum reagent IDs to prevent mis‑issuance.
- Analytics: orthogonal testing of NTP identity and residual PolyP (HPLC, capillary electrophoresis, phosphorus assays) before or during IVT.
- Cybersecurity: protect recipe IP and setpoints in distributed plants; implement role‑based access for automated skids producing on‑demand RNA.
Regulatory hurdles before GMP adoption
Bringing a new phosphorylation system into GMP RNA production requires rigorous raw‑material qualification, impurity mapping, and enzyme lifecycle validation. Core expectations are already mapped out in internationally harmonized guidance for active substance manufacturing, and regulators are likely to treat MAN PPK2 as a critical raw material with system‑level impact on the drug substance process.
- Quality systems for raw materials and intermediates (lot traceability, retest intervals, bioburden/endotoxin control)
- Process validation for one‑pot NTP generation and IVT coupling (worst‑case runs, hold‑time studies, leachables from single‑use components)
- Analytical methods to quantify residual PolyP, unreacted NMP/NDP, and off‑target nucleotides
- Change control and comparability protocols when transitioning from purchased NTPs to in situ generation
For organizations planning tech transfer, the starting point remains the globally adopted GMP framework for drug substance manufacturing under ICH Q7. A practical route is to structure control strategies against that standard while layering biologics‑specific expectations from regional agencies, including emergency‑use or accelerated‑approval pathways that may govern future pandemic vaccines.
Key technical risks and safeguards
Against that regulatory backdrop, technical risk management becomes an exercise not only in chemistry but also in institutional trust: ministries of health and funding bodies will scrutinize how robustly manufacturers have stress‑tested the new system.
- Off‑target products: verify absence of unwanted polyphosphorylated species that could inhibit polymerases; include release tests with functional IVT yield readouts.
- Enzyme compatibility: confirm MAN PPK2 does not persist at levels that interfere with capping, tailing, or modification steps post‑transcription.
- Modified nucleotides: assess separately; broad activity on canonical bases does not guarantee performance with base‑ or sugar‑modified substrates used in therapeutic mRNA.
- Supply chain: build dual sourcing for PolyP and nucleoside precursors; define chain‑length specs for PolyP to stabilize kinetics.
Timeline and what practitioners should track
With the basic science now public, the clock shifts from discovery to development. For policy makers and procurement agencies, the next two to three years will determine whether MAN PPK2 becomes a niche tool or a standard feature of sovereign mRNA platforms.
- January 8, 2026: peer‑reviewed study appears in Nature Communications (DOI: 10.1038/s41467-025-68012-9).
- January 22, 2026: public announcement highlights single‑enzyme, PolyP‑powered NTP generation and one‑pot mRNA synthesis.
- Next milestones to monitor:
- Enzyme stability data under GMP‑like storage and lyophilization conditions
- Performance with clinically relevant IVT templates at liter scale
- Comparability packages for switching NTP supply strategies in regulated programs
Market implications across biotech and public sector
If MAN PPK2 performs as advertised at scale, it could influence not just corporate margins but national strategies for vaccine and therapeutic autonomy.
- mRNA vaccines and therapeutics: potential reduction in COGS and shorter lead times for clinical and commercial batches.
- Diagnostics and research kits: on‑board NTP regeneration in lyophilized IVT kits could cut costs for academic and point‑of‑care use.
- Public‑sector readiness: on‑demand RNA production using stable PolyP stocks strengthens biodefense and outbreak response infrastructure, supporting government efforts to maintain regional manufacturing hubs rather than relying solely on a handful of multinational suppliers.
Primary materials
- Institute of Science Tokyo announcement: MAN PPK2 as a PolyP‑powered, single‑enzyme route to all four RNA NTPs, detailing the enzyme’s broad substrate scope and its performance in one‑pot IVT reactions.
- Global GMP framework for manufacturing drug substances applies to enzyme‑enabled NTP generation and IVT coupling, shaping how regulators will assess control strategies, comparability, and lifecycle management for MAN PPK2‑based processes.
